Compare Incyte Corporation (INCY) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Oatly Group AB - ADR — how do they compare? Incyte Corporation trades at $117.54 (market cap $23.11B), while Oatly Group AB - ADR trades at $9.46 (market cap $308.50M). The key difference: Incyte Corporation is far larger — about 74.9× Oatly Group AB - ADR's market cap, and Incyte Corporation is trading nearer its 52-week high, Oatly Group AB - ADR nearer its low. Which is the better fit depends on your goals.
| INCY | OTLY | |
|---|---|---|
Market Cap | $23.11B | $308.50M |
Sector | Health | Consumer Staples |
52-Week High | $118.52 | $18.54 |
52-Week Low | $67.38 | $8.03 |
Enterprise Value | $19.13B | $806.12M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
OTLY trades at $9.81, down 2.29% on the day, with a bullish technical signal from moving averages. Revenue grew to $862.46M in 2025, but net losses persist at -$152.77M. Cash burn remains a concern with negative operating cash flow of -$23.72M. The company announced Q2 2026 results for July 22, 2026, and continues brand partnerships like the Nespresso iced coffee collaboration.
Outlook is mixed: strong brand and revenue growth offer potential, but profitability challenges and high debt-to-asset ratio of 66.53% pose significant risks. Analyst consensus is divided with 44% buy ratings, yet cash runway constraints highlighted by Seeking Alpha on 2026-05-14 require careful monitoring for equity investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
